Overall, understanding the difference between dry and wet AMD is important for protecting your vision. Although both types affect the macula, they behave differently and require different management strategies. Early assessment and regular eye care can help support better long-term vision outcomes.<\/p>\n
What Is Wet AMD?<\/h2>\n
Wet AMD occurs when abnormal blood vessels begin to grow beneath your retina, particularly under the macula. These fragile blood vessels can leak fluid or blood, causing damage to the delicate retinal tissues that are responsible for your central vision. As a result, you may experience blurred vision, distorted images or a sudden decline in your ability to see fine details.<\/p>\n
This abnormal blood vessel growth is often driven by a signalling protein called vascular endothelial growth factor (VEGF). When VEGF levels increase, it can encourage the formation of new blood vessels that are weak and more likely to leak, contributing to the progression of wet AMD.<\/p>\n
Understanding the role of VEGF was a major breakthrough in eye care because it allowed researchers to develop treatments that specifically target this pathway. By blocking VEGF activity, modern therapies can help reduce abnormal blood vessel growth and protect your vision from further damage.<\/p>\n
The Need for Better AMD Treatments<\/h2>\n
Before anti-VEGF medicines became available, treatment options for wet AMD were limited. If you were diagnosed with wet AMD during this time, there were fewer effective ways to control the condition and protect your vision from ongoing damage.<\/p>\n
Some existing treatments focused on slowing the growth of abnormal blood vessels beneath your retina, but the results were often limited. Many people with wet AMD still experienced gradual or rapid vision loss despite receiving available therapies, highlighting the need for more effective treatment approaches.<\/p>\n
Researchers recognised that a better solution was needed one that could target important biological pathways involved in abnormal vessel growth and leakage This search led to the development of therapies designed to block VEGF activity, creating a new approach to managing wet AMD and improving outcomes for patients.<\/p>\n
What Is Anti-VEGF Therapy?<\/h2>\n
Anti-VEGF therapy is a type of treatment designed to block the activity of vascular endothelial growth factor (VEGF), a protein that plays an important role in the growth of abnormal blood vessels beneath your retina. By targeting this specific pathway, these medicines help target a key pathway involved in abnormal vessel growth and leakage in wet AMD.<\/p>\n
When VEGF activity is reduced, anti-VEGF medicines can help control fluid leakage and swelling within your retina. This may help stabilise your vision and, in some cases, improve visual outcomes by reducing the effects of abnormal blood vessel growth.<\/p>\n
This treatment approach changed the way your eye specialist manages wet AMD. Instead of only trying to slow disease progression, doctors can now use targeted therapies that directly address the biological processes contributing to vision loss.<\/p>\n
The Purpose of the MARINA Study<\/h2>\n
The MARINA study was designed to find out whether an anti-VEGF medicine could improve vision outcomes for people with wet AMD. Researchers wanted to understand whether this targeted treatment could help control the disease process and provide better protection for your sight compared with sham treatment.<\/p>\n
The study focused on whether anti-VEGF therapy could slow the progression of wet AMD and help you maintain or even improve your vision over time. This was particularly important because many people with wet AMD previously faced a high risk of significant central vision loss.<\/p>\n
The findings from the MARINA study provided valuable evidence about the effectiveness of targeted retinal treatments. The research helped change how your eye specialist approaches wet AMD by supporting the use of therapies that directly target the underlying causes of retinal damage.<\/p>\n
Clinical Trial Design<\/h2>\n
The MARINA study was a large, randomised, double-blind, controlled clinical trial created to carefully evaluate whether anti-VEGF treatment could improve outcomes for people with wet AMD. When you look at how new treatments are developed, this type of study design is important because it helps ensure the results are accurate and trustworthy.<\/p>\n
Participants were randomly assigned to receive either an anti-VEGF treatment or sham injections. Neither you nor the researchers knew which treatment was being given during the controlled phase, helping to prevent expectations from influencing the results.<\/p>\n
This approach allowed researchers to compare outcomes fairly and understand the treatment effects of ranibizumab compared with sham. The reliable evidence from the MARINA study helped your eye specialist better understand how anti-VEGF therapy could support people with wet AMD and protect their vision.<\/p>\n
Who Participated in the Study?<\/h2>\n
The MARINA study included people who had been diagnosed with specific types of wet AMD affecting the central part of their retina. If you have wet AMD, the condition can affect your macula, making it harder for you to see fine details and carry out everyday activities that rely on clear central vision.<\/p>\n
Participants in the study had vision problems caused by abnormal blood vessel growth beneath the macula. By including people with minimally classic or occult-with-no-classic subfoveal CNV meeting the trial eligibility criteria, researchers could examine whether anti-VEGF treatment could help control the damage caused by these fragile blood vessels.<\/p>\n
This allowed the study team to understand how effective the treatment could be in real situations where you may be experiencing ongoing retinal changes. The results provided important information about whether anti-VEGF therapy could help slow vision loss and improve outcomes for people living with wet AMD.<\/p>\n
Impact on Retinal Medicine<\/h2>\n
![\"\"](\"https:\/\/www.eyecliniclondon.com\/blog\/wp-content\/uploads\/2026\/04\/imagess-58.jpg\")
<\/p>\n
The MARINA study had an impact that extended far beyond the treatment of wet AMD. By showing that targeting a specific biological pathway could improve outcomes, it opened the door to new approaches in ophthalmology and changed how researchers thought about treating retinal diseases.<\/p>\n
The success of anti-VEGF therapy encouraged further research into similar targeted treatments for other eye conditions. For you, this means that advances inspired by studies like MARINA may continue to improve the options available for managing different retinal disorders in the future.<\/p>\n
The study helped shape modern retinal medicine by demonstrating the value of precision treatments that act on specific biological pathways involved in retinal disease. Today, your eye specialist can benefit from a growing range of therapies developed through this approach, offering better opportunities for preserving vision.<\/p>\n
Measuring Vision Improvement<\/h2>\n
Researchers assessed the success of the MARINA study by measuring changes in visual acuity, which refers to how clearly you can see details at different distances. This helped the study team understand whether anti-VEGF treatment could protect your vision or improve visual outcomes over time.<\/p>\n
Standard eye charts were used throughout the study to measure whether participants maintained their existing vision, experienced improvement or had further vision loss. These consistent assessments allowed researchers to track changes in sight accurately.<\/p>\n
By using clear and reliable vision measurements, the study provided strong evidence about the effectiveness of anti-VEGF therapy. The results helped your eye specialist understand how targeted treatments could play an important role in managing wet AMD and protecting your central vision.<\/p>\n
Major Findings of the MARINA Study<\/h2>\n
The MARINA study showed that monthly ranibizumab produced substantially better visual outcomes than sham treatment in the population studied. For you, this represented an important change in the way this condition could be managed, as previous options offered limited ability to protect your vision.<\/p>\n
Many participants who received anti-VEGF therapy were able to maintain their existing vision during the study, while some experienced meaningful improvements in their sight. These results showed that targeted treatment could help reduce the impact of abnormal blood vessel growth beneath the retina.<\/p>\n
The findings from the MARINA study marked a major breakthrough in retinal care. They changed how your eye specialist approaches wet AMD by introducing a treatment strategy that focuses on targeting a key angiogenic pathway involved in neovascular AMD rather than only managing the effects of the disease.<\/p>\n
Evidence Note: What Did MARINA Actually Find?<\/strong><\/p>\n MARINA enrolled 716 patients and randomly assigned them to monthly ranibizumab 0.3 mg, monthly ranibizumab 0.5 mg or sham injections for 24 months.<\/p>\n At one year, 94.5% of patients receiving 0.3 mg and 94.6% receiving 0.5 mg lost fewer than 15 visual-acuity letters, compared with 62.2% receiving sham treatment.<\/p>\n Meaningful visual improvement was also more common with ranibizumab. A gain of at least 15 letters occurred in 24.8% of the 0.3 mg group and 33.8% of the 0.5 mg group, compared with only 5.0% of the sham group.<\/p>\n Average visual acuity improved by 6.5 letters and 7.2 letters in the ranibizumab groups, while the sham group lost an average of 10.4 letters.<\/p>\n For patients, the significance was profound. MARINA showed that treatment could do more than slow deterioration. For many people in the population studied, vision could be preserved, and for a substantial proportion, clinically meaningful improvement was possible.<\/p>\n One of the most important discoveries from the MARINA study was that anti-VEGF therapy could help reduce the risk of severe vision decline in people with wet AMD. If you are diagnosed with this condition, protecting your central vision is a key goal because it plays an essential role in everyday activities such as reading, driving and recognising faces.<\/p>\n Before anti-VEGF treatments became available, many people with wet AMD faced a significant risk of progressive central vision loss. Treatment options were limited, and it was often difficult to prevent the condition from causing further damage to your sight.<\/p>\n The results of the MARINA study changed expectations for people living with wet AMD. By showing that targeted treatment could help preserve vision, the study gave you and other patients new hope for better long-term management of this retinal condition.<\/p>\n Two-Year Clinical Insight<\/strong><\/p>\n The benefit of ranibizumab was maintained through the second year of MARINA. At 24 months, approximately nine in ten ranibizumab-treated patients had avoided losing 15 or more visual-acuity letters, compared with just over half of patients in the sham group. Around one-quarter to one-third of ranibizumab-treated patients had gained at least 15 letters.<\/p>\n However, these results were achieved with fixed monthly injections. They should not be interpreted as evidence that every patient receiving modern anti-VEGF therapy must continue injections every month indefinitely.<\/p>\n Following the success of the MARINA study, anti-VEGF injections became a standard treatment approach for people with wet AMD. If you are diagnosed with this condition today, your eye specialist may recommend these therapies because they have been shown to help manage abnormal blood vessel growth and protect your vision.<\/p>\n Retinal specialists around the world adopted anti-VEGF treatment because of its ability to preserve sight and improve outcomes for many people. This approach changed the way doctors managed wet AMD by focusing on targeting the underlying causes of retinal damage.<\/p>\n The introduction of anti-VEGF therapy transformed the outlook for people living with wet AMD. Instead of facing limited options and a high risk of severe vision loss, you now have access to treatments that can help maintain your vision and support your quality of life.<\/p>\n UK Clinical Practice Note<\/strong><\/p>\n Current UK care has developed considerably since the fixed monthly treatment schedule tested in MARINA.<\/p>\n NICE recommends urgent referral for suspected active wet AMD to a macula service, normally within one working day. OCT should be offered as part of the assessment, and when anti-VEGF treatment is recommended for confirmed active wet AMD, treatment should start as soon as possible and within 14 days of referral to the macular service.<\/p>\n NICE also recommends ongoing OCT monitoring of both eyes for people with active wet AMD. Treatment and monitoring are therefore based on current clinical findings, imaging and individual circumstances rather than simply repeating the original MARINA monthly schedule for every patient.<\/p>\n The Royal College of Ophthalmologists’ 2024 commissioning guidance similarly emphasises prompt referral, OCT-based monitoring and timely treatment. It also recognises the importance of monitoring treatment delays, visual outcomes, injection numbers and continued engagement with long-term care.<\/p>\n Anti-VEGF therapy is not usually a one-time treatment, and you may need ongoing injections and regular monitoring to manage wet AMD effectively. Since the condition can become active again over time, your eye specialist will closely track changes in your retina and adjust your treatment plan when needed.<\/p>\n During your follow-up appointments, your ophthalmologist can assess whether there are signs of fluid leakage, swelling or new abnormal blood vessel activity. These regular checks help your doctor decide when you may need another injection to continue protecting your vision.<\/p>\n Consistent follow-up is essential for supporting favourable long-term outcomes with anti-VEGF therapy. By attending your appointments and following your personalised treatment schedule, you can support long-term vision preservation and appropriate disease control of maintaining your vision and managing wet AMD over the long term.<\/p>\n After the success of anti-VEGF therapy in studies like MARINA, researchers continued to develop new medicines and treatment strategies for wet AMD. If you are living with this condition, these advances aim to make your care more effective while reducing some of the challenges associated with long-term treatment.<\/p>\n Newer therapies are being designed to extend the time between injections, improve convenience and help maintain strong vision outcomes. This may mean fewer clinic visits for you while still receiving the ongoing support needed to manage retinal activity and protect your sight.<\/p>\n Innovation in retinal medicine continues to build on the foundation created by early studies such as MARINA. As research progresses, you may benefit from treatment options that are increasingly personalised, effective and easier to manage over the long term.<\/p>\n Long-Term Perspective: What Happened Years Later?<\/strong><\/p>\n Longer-term follow-up of selected patients originally enrolled in MARINA or ANCHOR and later HORIZON showed that neovascular AMD remains a chronic condition requiring continued attention.<\/p>\n In the SEVEN-UP cohort, 65 participants were assessed at a mean of 7.3 years after entry into the original pivotal trials. Compared with their original baseline vision, 43% had stable or improved letter scores, while 34% had declined by 15 letters or more. OCT still detected active exudative disease in 68% of study eyes, and 46% were receiving ongoing anti-VEGF treatment.<\/p>\n These results should be interpreted cautiously. SEVEN-UP was a small, selected, non-interventional cohort drawn from participants in several previous studies, so it does not represent a seven-year randomised extension of MARINA alone.<\/p>\n For patients, the broader message is that the first two years of treatment can provide major benefit, but neovascular AMD remains a long-term disease that may reactivate or progress over time. Continued monitoring remains important.<\/p>\n Clinical Safety Note: When to Seek Urgent Help After an Eye Injection<\/strong><\/p>\n Mild discomfort or redness can occur after an intravitreal injection. However, if your eye becomes increasingly red, painful, sensitive to light or swollen, or if your vision becomes worse after treatment, seek urgent ophthalmic advice.<\/p>\n These symptoms can indicate a complication requiring prompt assessment. Your retinal team should explain how to obtain urgent help after treatment and what symptoms you should report immediately.<\/p>\n Vision loss caused by wet AMD can have a significant impact on your independence and everyday activities. Tasks that you may once have taken for granted, such as reading, recognising faces, using technology or moving around confidently, can become more difficult when your central vision is affected.<\/p>\n By helping you preserve your central vision, anti-VEGF therapy has improved quality of life for many people living with wet AMD. Maintaining better vision can allow you to continue enjoying daily routines, stay connected with others and remain more independent for longer.<\/p>\n The benefits of this treatment go beyond clinical measurements on an eye chart. While improved vision results are important, the ability for you to maintain confidence, independence and participation in everyday life represents one of the greatest impacts of advances in retinal care.<\/p>\n Although treatments for wet AMD have improved significantly, early diagnosis remains one of the most important factors in protecting your vision. When changes in your retina are detected early, your eye specialist can begin treatment sooner and help reduce the risk of further damage.<\/p>\n If wet AMD is identified before extensive retinal damage occurs, you may have a better chance of preserving your central vision. Early assessment allows your ophthalmologist to monitor changes closely and recommend appropriate treatment before the condition progresses.<\/p>\n Regular eye examinations are especially important if you have a higher risk of developing AMD. By attending routine check-ups and seeking medical advice if you notice changes in your vision, you can take an active role in protecting your eye health and maintaining your quality of life.<\/p>\n If you are receiving anti-VEGF therapy for wet AMD, ongoing monitoring is essential to track how your retina is responding to treatment. Regular follow-up appointments allow your eye specialist to check for any changes and make sure your condition remains under control.<\/p>\n Advanced imaging technologies, such as optical coherence tomography (OCT), provide detailed views of your retina and help detect changes that may not be visible during a standard eye examination. These scans allow your ophthalmologist to assess fluid levels, retinal structure and signs of disease activity.<\/p>\n By using these monitoring tools, your specialist can make more personalised treatment decisions based on your individual needs. This approach helps ensure you receive treatment at the right time while supporting the appropriate treatment and monitoring decisions for your individual condition.<\/p>\nPreventing Vision Loss<\/h2>\n
Changing the Standard of Care<\/h2>\n
Ongoing Treatment and Monitoring<\/h2>\n
Advances Following MARINA<\/h2>\n
Improving Patient Quality of Life<\/h2>\n
![\"\"](\"https:\/\/www.eyecliniclondon.com\/blog\/wp-content\/uploads\/2026\/07\/imagess-62.jpg\")
<\/p>\nThe Role of Early Diagnosis<\/h2>\n
Monitoring AMD After Treatment<\/h2>\n
What Is Checked During Wet AMD Follow-Up?<\/h2>\n
![\"\"](\"https:\/\/www.eyecliniclondon.com\/blog\/wp-content\/uploads\/2026\/07\/imagess-63.jpg\")
<\/p>\n